Severe and prolonged neutropenia is a common consequence of cancer chemotherapy and is associated with an increased risk of severe infections. Transfusion of donor neutrophils is a viable option to combat this, but obtaining matched donors is a dilemma. There are pharmacologic interventions aimed at shortening the duration of neutropenia and combatting infection; however, infection risk remains high due to a lack of response to these treatments in many patients.
Mesenchymal stem cells therapy is raved as being the champion of immune modulators. Can the promise be realized?